Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (October 2021)
22 slides from Relmada Therapeutics's investor presentation, Oct 7, 2021
Slide 1: Targeting Major Advances in Treatment of CNS Disorders
Targeting Major Advances in Treatment of CNS Disorders October 2021 I Nasdaq: RLMD 1
Slide 2: Disclosures
Disclosures Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - looking statements.” These sta tem
Slide 3: Investment Highlights
Investment Highlights Highly Compelling Opportunity in REL - 1017 Multiple Catalysts Expected Over Next 18 Months CNS Focus with Lead Program in Major Depressive Disorder (MDD) CNS= Central Nervous System **Our fiscal year end is December 31. The periods referred to in this slide are calendar years
Slide 4: Major Depressive Disorder
Major Depressive Disorder & REL - 1017
Slide 5: Prevalence of Depression
Prevalence of Depression ~10M • 50% of patients in the US experiencing a major depressive episode in the last year received medication treatment 1 • 40% require combination Rx 2 ~19.3M • Individual adults in the US had at least one major depressive episode in 2019 1 >280M • People of all ages suffer
Slide 6: Limitations of Current Treatments for MDD
Limitations of Current Treatments for MDD ~65% MDD patients do not respond to first antidepressant treatment 1 Standard antidepressants take 2 - 4 weeks to reach efficacy 1 MDD = major depressive disorder 1. Trivedi MH, et al. Am J Psychiatry. 2006;163:28 - 40; 2. Ashton AK, et al. Curr Ther Res.
Slide 7: Differentiated Profile of REL-1017
Differentiated Profile of REL - 1017 • Novel Mechanism of Action: preferentially targets NMDAR channels associated with MDD • Available clinical data demonstrated: • Robust, rapid and sustained statistically significant antidepressant effects on all tested scales 2 • Rapid onset: significant efficac
Slide 8: Phase 1 & 2 Efficacy & Safety Data
REL - 1017 Ph 1 & 2 Efficacy & Safety Data
Slide 9: Phase 1 SAD & MAD Studies, Data Published 2019
Phase 1 SAD & MAD Studies for REL - 1017, Data Published 2019 PK = pharmacokinetics; PD = pharmacodynamics; MTD: =maximum tolerated dose; C max = maximum plasma concentration ; AUC 0 - inf = area under the curve 0 to infinite time; AUC t = area under the curve to the end of dosing period; N = number
Slide 10: Phase 2 Study: Primary Efficacy Endpoint
Day 2 Day 4 Day 7 Day 14 5 0 - 5 - 25 Least - Square Mean Change in MADRS - 10 - 15 - 20 P=0.0103; d=0.9 P=0.0039; d=1.0 P=0.0308; d=0.7 P=0.0122; d=0.8 P=0.0096; d=0.8 P=0.0087; d=0.9 P=0.9092; d=0.0 P=0.4340; d=0.3 Placebo REL - 1017 25 mg REL - 1017 50 mg Phase 2 Study REL - 1017: Primary Efficac
Slide 11: Safety & Tolerability Findings from Phase 2
Safety & Tolerability Findings from Phase 2 • Only Mild and Moderate AEs – no SAEs • No increased prevalence of specifically relevant organ group AEs in treatment groups vs placebo • No evidence of opiate effects or withdrawal symptoms in treatment groups vs placebo • No evidence of treatment - indu
Slide 12: Primary Endpoint - Drug Liking vs. Oxycodone
Primary Endpoint - Drug Liking [Emax] REL - 1017 vs. Oxycodone Statistic Parameter Placebo REL - 1017 25 mg REL - 1017 75 mg REL - 1017 150 mg Oxycodone 40 mg n 44 44 44 44 44 Mean 51.7 53 58.2 64.9 85 Median 50 50 50 58 89 SD 4.28 8.67 14.98 16.74 15.4 SE 0.64 1.31 2.26 2.52 2.32 Treatment 1 Treatm
Slide 13: RELIANCE: The Phase 3 Program
RELIANCE: The Phase 3 Program for REL - 1017
Slide 14: Phase 3 Program for the Adjunctive Treatment of MDD
REL - 1017 Phase 3 Program for the Adjunctive Treatment of MDD 14 Initiated December 2020 Two sister two - arm, placebo - controlled pivotal studies: • In MDD patients with inadequate response to 1 - 3 ADT (n= ~364 per study) • Primary Endpoint: Change in MADRS at Day 28 • Key Secondary Endpoints: •
Slide 15: Pivotal Phase 3 Trial Design
Screening confirms MDE with inadequate response to 1 - 3 ADT ADT + 25 mg REL - 1017 ADT + Matching Placebo Pivotal Phase 3 Trial Design 15 Primary Endpoint: • Change in MADRS at Day 28 Key Secondary Endpoints: • Change in MADRS score at Day 7 • Change in CGI - S score at Day 28 1:1 randomization (n=
Slide 16: Relmada Development Programs & Timeline
Relmada Development Programs & Timeline* Program H1 21 H2 21 H1 22 H2 22 1H 2023 2H 23 REL - 1017 Psilocybin and Derivates RELIANCE - III: MDD Monotherapy RELIANCE I: 1 st Pivotal Adjunctive MDD trial RELIANCE II: 2 nd Pivotal Adjunctive MDD trial RELIANCE - OLS: Long - Term, Open - Label Study in M
Slide 17: Novel Psilocybin and Derivates
Novel Psilocybin and Derivates
Slide 18: Novel Psilocybin and Derivates
Novel Psilocybin and Derivates • July 2021 announcement of licensing agreement: development and commercial rights to a novel psilocybin and derivate program • Complementary focus: potential therapies for neurodegenerative conditions • Synergy in neuroplasticity: Expands R&D portfolio while building
Slide 19: Corporate Information
B Corporate Information
Slide 20: Financial Overview
Financial Overview Cash, Cash Equivalents & Short - Term Investments (as of 6/30/2021) $109.1 million Warrants Outstanding (as of 6/30/21, weighted average exercise price, $13.22) ~2.8 million Operating Cash Burn 2Q21 $17.2 million Common Shares Outstanding* (as of 6/30/2021) ~17.5 million 20 *As co
Slide 21: Investment Highlights
Investment Highlights Highly Compelling Lead Product Opportunity in REL - 1017 Key Catalysts Expected Over Next 3 - 18 Months Focus on CNS diseases and Lead Program in Major Depressive Disorder (MDD) CNS= Central Nervous System;; MDD = major depressive disorder; MOA = mechanism of action **Our fisca
Slide 22: 6S
3 6S 6
Relmada Therapeutics — Investor Presentation (October 2021) on 6ix